CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sam Whiting
Calithera Biosciences
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
38 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the University of Arizona Cancer Center
Tucson, Arizona, United States
- Highlands Oncology Group
Rogers, Arkansas, United States
- Los Angeles Hematology Oncology Medical Group
Los Angeles, California, United States
- Ucla Department of Medicine - Hematology/oncology
Los Angeles, California, United States
- Stanford Cancer Center
Stanford, California, United States
- Florida Cancer Specialists- South
Fort Myers, Florida, United States
- Florida Cancer Specialists- North
St. Petersburg, Florida, United States
- University Cancer & Blood Center, Llc
Athens, Georgia, United States
- Northwest Georgia Oncology Centers, P.C.
Marietta, Georgia, United States
- St. Luke'S Mountain States Tumor Institute
Boise, Idaho, United States
- Northwestern University
Chicago, Illinois, United States
- Parkview Research Center
Fort Wayne, Indiana, United States
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
- Norton Cancer Institute, Norton Healthcare Pavilion
Louisville, Kentucky, United States
- Ochsner Clinical Foundation
New Orleans, Louisiana, United States
- Anne Arundel Medical Center Oncology and Hematology
Annapolis, Maryland, United States
- University of Maryland, Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, United States
- Metro-Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, United States
- Mercy Clinic Oncology & Hematology
Joplin, Missouri, United States
- Scri Hca Midwest
Kansas City, Missouri, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- St. Vincent Frontier Cancer Center
Billings, Montana, United States
- Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
- North Shore Hematology Oncology Associates Pc Dba Ny Cancer and Blood Specialists
East Setauket, New York, United States
- Nyu Winthrop Hospital - Cancer Clinical Trials Oncology/hematology
Mineola, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Suny Upstate Medical University
Syracuse, New York, United States
- Montefiore Medical Center
The Bronx, New York, United States
- University of Cincinnati Medical Center
Cincinnati, Ohio, United States
- Ann B. Barshinger Cancer Institute / Lancaster General Hospital
Lancaster, Pennsylvania, United States
- Monongahela Valley Hospital
Monongahela, Pennsylvania, United States
- Charleston Hematology Oncology Associates,pa
Charleston, South Carolina, United States
- Ut/erlanger Oncology & Hematology
Chattanooga, Tennessee, United States
- Sarah Cannon Research Institute - Tennessee Oncology
Nashville, Tennessee, United States
- the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
- Utah Cancer Specialists
Salt Lake City, Utah, United States
- Wenatchee Valley Hospital and Clinics
Wenatchee, Washington, United States
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Sept 2017
- Primary completion
- 26 Apr 2019
- Completion
- 1 Jun 2020
- Last update posted
- 15 Sept 2022
- Registered enrollment
- 69
- Registry id
- NCT03163667
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.